Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Background: There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in patients with CRPC aged 75 years or older in a multiinstitutional study. Methods: We...

Full description

Bibliographic Details
Main Authors: Takashi Matsumoto, Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Prostate International
Subjects:
Cabazitaxel
Castration-resistant prostate cancer
Efficacy
Safety
The elderly
Online Access:http://www.sciencedirect.com/science/article/pii/S228788822030088X

Internet

http://www.sciencedirect.com/science/article/pii/S228788822030088X

Similar Items